July 2020 FDA Recall Drug by Taro Pharmaceuticals U.s.a., Inc.
D-1496-2020 - Failed Content Uniformity

This Class III drug recall was voluntarily initiated by Taro Pharmaceuticals U.s.a., Inc. on July 20, 2020 for the product Drug. The FDA reported the reason for recall as failed content uniformity. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1496-2020

Reason for Recall
Failed Content Uniformity: bulk lot used to make these two lots was found to have failed content uniformity.
Initiated
07-20-2020
Reported
08-19-2020
Quantity
7632 tubes

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Taro Pharmaceuticals U.S.A., Inc.
Nationwide in the U.S.
Clobetasol Propionate Cream USP, 0.05%, a) 15 g tube, NDC: 60429-902-15; b) 45 g tube, NDC: 60429-902-45, Rx Only, For External Use Only, Not for Ophthalmic Use, Mfd by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Marketed by: Golden State Medical Supply, Inc. Camarillo, CA 93012.

Batch or Lot Expiration Information

Lot# a) AB28353, Exp 12/31/2021; b) AB40178, Exp 12/31/2021